Literature DB >> 18360700

An evolutionary model for initiation, promotion, and progression in carcinogenesis.

T L Vincent1, R A Gatenby.   

Abstract

Human carcinogenesis is a multistep process in which epithelial cells progress through a series of premalignant phenotypes until an invasive cancer emerges. Extensive experimental observations in carcinogenesis have demonstrated this process can be divided into three general eras: initiation, promotion, and progression. However, this empirically derived, tissue-level explanation of carcinogenesis has not been reconciled with the step-wise genotypic and phenotypic changes encompassed in evolutionary paradigms such as the Feoron-Vogelstein diagram. Here, we analyze an evolutionary model of cellular dynamics that defines mutual interactions of cellular and subcellular events and tissue level changes in tumor growth and morphology. Results are expressed using an adaptive landscape that illustrates the evolutionary potential of cells that allow them to adapt to specific microenvironmental selection forces. It is shown that normal epithelial cells have a novel adaptive landscape that permits coexistence of normal cellular populations but also allows invasion by mutant phenotypes. Subsequent cancer evolution is possible due to a relaxation of tissue growth constraints (as mediated by cell-cell and cell-extracellular matrix interactions) and adaptations in response to perturbations in microenvironmental substrate concentrations (due to separation of evolving tumor cells from their blood supply by an intact basement membrane). Simulations, based on the dynamic model, produce three distinct stages of carcinogenesis that are consistent with the initiation, promotion, and progression stages observed experimentally. The simulations provide insight into the underlying cellular and microenvironmental dynamics that govern these empirical observations and suggest novel prevention strategies that may be tested experimentally.

Entities:  

Mesh:

Year:  2008        PMID: 18360700

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  34 in total

1.  Dispersal evolution in neoplasms: the role of disregulated metabolism in the evolution of cell motility.

Authors:  C Athena Aktipis; Carlo C Maley; John W Pepper
Journal:  Cancer Prev Res (Phila)       Date:  2011-09-19

2.  Natural products and colon cancer: current status and future prospects.

Authors:  Subapriya Rajamanickam; Rajesh Agarwal
Journal:  Drug Dev Res       Date:  2008-11-01       Impact factor: 4.360

Review 3.  Convergence of nanotechnology and cancer prevention: are we there yet?

Authors:  David G Menter; Sherri L Patterson; Craig D Logsdon; Scott Kopetz; Anil K Sood; Ernest T Hawk
Journal:  Cancer Prev Res (Phila)       Date:  2014-07-24

4.  Evolution and impact of subclonal mutations in chronic lymphocytic leukemia.

Authors:  Dan A Landau; Scott L Carter; Petar Stojanov; Aaron McKenna; Kristen Stevenson; Michael S Lawrence; Carrie Sougnez; Chip Stewart; Andrey Sivachenko; Lili Wang; Youzhong Wan; Wandi Zhang; Sachet A Shukla; Alexander Vartanov; Stacey M Fernandes; Gordon Saksena; Kristian Cibulskis; Bethany Tesar; Stacey Gabriel; Nir Hacohen; Matthew Meyerson; Eric S Lander; Donna Neuberg; Jennifer R Brown; Gad Getz; Catherine J Wu
Journal:  Cell       Date:  2013-02-14       Impact factor: 41.582

Review 5.  Hybrid models of tumor growth.

Authors:  Katarzyna A Rejniak; Alexander R A Anderson
Journal:  Wiley Interdiscip Rev Syst Biol Med       Date:  2011 Jan-Feb

6.  TGFBI expression is associated with a better response to chemotherapy in NSCLC.

Authors:  Marta Irigoyen; María J Pajares; Jackeline Agorreta; Mariano Ponz-Sarvisé; Elisabeth Salvo; María D Lozano; Ruben Pío; Ignacio Gil-Bazo; Ana Rouzaut
Journal:  Mol Cancer       Date:  2010-05-28       Impact factor: 27.401

7.  Genome based cell population heterogeneity promotes tumorigenicity: the evolutionary mechanism of cancer.

Authors:  Christine J Ye; Joshua B Stevens; Guo Liu; Steven W Bremer; Aruna S Jaiswal; Karen J Ye; Ming-Fong Lin; Lesley Lawrenson; Wayne D Lancaster; Markku Kurkinen; Joshua D Liao; C Gary Gairola; Malathy P V Shekhar; Satya Narayan; Fred R Miller; Henry H Q Heng
Journal:  J Cell Physiol       Date:  2009-05       Impact factor: 6.384

8.  Cancer treatment as a game: integrating evolutionary game theory into the optimal control of chemotherapy.

Authors:  Paul A Orlando; Robert A Gatenby; Joel S Brown
Journal:  Phys Biol       Date:  2012-11-29       Impact factor: 2.583

Review 9.  Clonal evolution in hematological malignancies and therapeutic implications.

Authors:  D A Landau; S L Carter; G Getz; C J Wu
Journal:  Leukemia       Date:  2013-08-27       Impact factor: 11.528

10.  Energy oversupply to tissues: a single mechanism possibly underlying multiple cancer risk factors.

Authors:  Daniel J Wu; Athena Aktipis; John W Pepper
Journal:  Evol Med Public Health       Date:  2019-01-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.